Experience with Ceftriaxone in the Treatment of Pulmonary Infections

Authors

  • Faroque A Khan Division of Pulmonary Medicine, Queens Hospital Center, Jamaica, New York
  • Joseph J Guarneri Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Rajinder Chitkara Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Phyllis DellaLatta Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Vincent LaBombardi Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Pravez Mir Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Suhail Raoof Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

DOI:

https://doi.org/10.5915/17-1-12717

Keywords:

Ceftriaxone, Pulmonary Infection, cephalosporin, Cefoxitin

Abstract

DOI: http://dx.doi.org/10.5915/17-1-12717

This paper describes the experience with a new third generation cephalosporin, Ceftriaxone, in the treatment of 60 patients with bacterial pulmonary infection. The unique pharmacokinetics of Ceftriaxone allow its usage twice a day in contrast to the 4 to 6 times a day for comparable antibiotics, with potential cost savings. Administered twice a day the overall cure rate was 94% with no serious side effects. A brief review of the clinical application of Cephalosporins in the treatment of infections is included.

Presented at the 17th Annual Convention of the Islamic Medical
Association in St. Louis, Missouri, August 10-12, 1984

Author Biographies

Faroque A Khan, Division of Pulmonary Medicine, Queens Hospital Center, Jamaica, New York

M.D., FCCP, FACP

Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

Joseph J Guarneri, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

PhD

Rajinder Chitkara, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

M.D., FCCP, FACP

Vincent LaBombardi, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

PhD

Pravez Mir, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

M.D.

Suhail Raoof, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

M.D.

Downloads

Published

1985-01-12

Issue

Vol. 17 No. 1 (1985)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).